Clinical Outcomes in Early Breast Cancer With Adjuvant Chemotherapy Plus Endocrine Therapy
This secondary anaysis of the TAILORx randomized clinical trial describes clinical outcomes for women with a high 21-gene recurrence score who received adjuvant chemotherapy plus endocrine therapy, a population expected to have a high distant recurrence rate with endocrine therapy alone.